Paediatric drugs and rare diseases

Lily suffers from Childhood Obliterative Bronchiolitis Lung

The use of unlicensed and off-label medicines, widespread among children affected by rare diseases resulted in inefficacy and serious side effects due to incorrect dosage. To counteract this, the EU Regulation on Paediatric Drugs was adopted by the European and the Council of Ministers in 2006.

The EU Regulation on Paediatric Drugs was adopted by the European and the Council of Ministers in 2006, after many years of advocacy work by stakeholders (academia, industry and patient groups) with EURORDIS at the forefront as early as December 2000. The Regulation was published in the Commission's official Journal in December 2006 and its implementation started in 2007.

The facts

  • Many medicines administered to children have not been developed for them (50 to 90 % according to 'Diseases and Countries in Europe')
  • Medicines used are those for adults; They are administered to children by decreasing quantities based on weight, which is extremely hazardous
  • Serious consequences, inefficacy and side effects often stem from incorrect dosage
  • The use of unlicensed and off-label medicines is widespread among children affected by rare diseases
  • Children are in a de facto situation of permanent and uncontrolled clinical trial, by taking drugs that have not been trialled for them
  • The Us regulation on paediatrics (Best Pharmaceuticals for Children Act) was adopted in 2002
  • There was no EU regulation on paediatrics until December 2006



Main measures of the EU regulation

  • Obligation of paediatric research (PIP - Paediatric investigation Plan) for every new drug developed for adults and having a potential use for children
  • Creation of an inventory of specific needs for paediatric medicinal products
  • Creation of a Paediatric committee including patient representatives at the European Medicines Agency (EMEA)
  • 6 month extension of the patent for the paediatric formula of existing 'still under-protection' adult medicine
  • 2 year extension of market exclusivity for orphan drugs for children (12 years in total instead of 10 years for adult orphan drugs)
  • Financial support via the EU research Framework Programme for Research on old (off-patent) drugs to study and develop paediatric use
  • Implementation of a process to avoid unnecessary clinical studies on children
  • Specific label products studied in children and authorised: the Paediatric Use Marketing Authorization (PUMA)



Several initiatives in the USA have created incentives and obligations for companies resulting in product information for over 100 drugs which now includes dosing, efficacy and safety information for children. Children in Europe, particularly those affected by rare diseases, will soon benefit similar conditions.


For more information:
European Medicines Agency (EMA)


Author: Eurordis
Photos: Jonathan © Starck/Eurordis; Laura © Nopanen/Eurordis; Arman © Matevosyan/Eurordis

Page created: 19/08/2009
Page last updated: 13/03/2012
 
 
The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseases, Rare Diseases International is a EURORDIS initiativeRare Disease International Bringing together patients, families and experts to share experiences in a moderated multilanguage forum, RareConnect is a EURORDIS initiative RareConnect An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases